Xarelto Bleeding Lawsuit Filed Over Inadequate Side Effect Warnings

Xarelto Bleeding Lawsuit

Start Claim Now

Xarelto Bleeding Lawsuit Filed Over Inadequate Side Effect Warnings

Patients taking Xarelto to reduce their risk of stroke may be at a greater risk of uncontrollable bleeding complications.

A product liability lawsuit has been filed against Bayer Healthcare and Johnson & Johnson’s Janssen unit, alleging that a California woman nearly died from uncontrollable hemorrhaging after using the controversial blood thinner, Xarelto. The complaint was brought by Shirley Boynton in the U.S. District Court for the Eastern District of New York on August 29, and alleges that Boynton suffered permanent and debilitating injuries as a result of inadequate warnings regarding Xarelto bleeding complications. If you have experienced an uncontrollable bleeding event and you believe Xarelto to be the cause, contact a skilled Xarelto attorney for legal help. You may have grounds to file a Xarelto lawsuit against Bayer and Johnson & Johnson, in order to pursue financial compensation for your injuries and medical expenses.

Xarelto Uncontrollable Bleeding Lawsuits

Boynton’s case joins a growing number of Xarelto lawsuits brought against Bayer and Janssen, all of which involve similar allegations that the drug makers failed to provide consumers and doctors with adequate warnings about the uncontrollable bleeding side effects of Xarelto treatment. The plaintiffs claim that the drug companies intentionally concealed information about Xarelto bleeding side effects in order to increase use of Xarelto over warfarin and other popular anticoagulant drugs. According to her complaint, Boynton first began Xarelto treatment in April 2012, and in August, she suffered a severe bleeding event that she claims caused her to experience permanent injuries and pain and suffering requiring life-long medical care.

No Reversal Agent for Xarelto Complications

Xarelto (rivaroxaban) belongs to a new generation of anticoagulant drugs known as “direct thrombin inhibitors,” which are designed to thin the blood and reduce the risk of blood clots and strokes. Xarelto was introduced in 2011 as a joint development by Bayer and Johnson & Johnson, and since it entered the market in the United States, it has been aggressively marketed by the drug companies as a superior alternative to warfarin, an anticoagulant that has been available in the U.S. for decades. Although Bayer and Janssen have claimed that Xarelto is easier to use than warfarin, since it requires less patient monitoring during treatment, a growing number of lawsuits filed over Xarelto side effects allege that, because there is no approved reversal agent for Xarelto, doctors are often unable to control Xarelto hemorrhage or bleeding events.

Contact an Experienced Xarelto Lawyer Today

Boynton’s Xarelto lawsuit pursues claims against the drug manufacturing companies for breach of warranty, negligence, strict product liability, fraudulent concealment, fraudulent misrepresentation, fraud, deceit and loss of consortium. If you believe you have been adversely affected by bleeding side effects of Xarelto, our consumer advocates at the Consumer Justice Foundation can help. We are dedicated to protecting the rights of consumers harmed by dangerous pharmaceutical drugs, and can help put you in touch with a knowledgeable Xarelto lawyer today. With a qualified Xarelto attorney on your side, you can protect your legal rights and seek fair and timely reimbursement for your Xarelto bleeding injuries.

Start Claim Now
Do you deserve compensation?

An attorney will review your situation for FREE and help you found out what really went wrong.

How Can We Reach You?

Please Explain Your Situation

By clicking the "Submit" button below, you agree that law firms you are matched with may contact you by telephone even if you are on a federal or state Do Not Call registry. Up to 10 law firms may respond to your request within approximately 2 weeks. In some cases 3 or more firms may respond to your request after 30 days. Use of this site is subject to our Terms of Use.
×